Company: INMB
Filing Date: 2025-03-07
Form Type: 424B5
Source: 0001213900-25-021719
Chunk: 17

Company: Inmune Bio, Inc.
Filing Date: 2025-03-07
Form: 424B5
Chunk 17
---
to investors purchasing shares in the offering as of September 30, 2024:

| Offering price per share (representing the average exercise price of the Warrants)                           |     | $ | 7.67 |
| Net tangible book value per share as of September 30, 2024                                                   |     | $ | 1.00 |
| Increase in net tangible book value per share attributable to this offering                                  |     | $ | 1.00 |
| As adjusted net tangible book value per share as of September 30, 2024, after giving effect to this offering |     | $ | 2.00 |
| Dilution per share to investor purchasing shares in this offering upon exercise of the Warrants              |     | $ | 5.67 |

We have also included a pro
forma dilution table to give effect the issuance of 411,776 shares of common stock under the Company’s at-the-market offering program
at an average price of $8.59 per share during February and March 2025 and the issuance of 108,000 shares of common stock for cash at an
exercise price of $3.91 per share during November 2024. Our pro forma net tangible book value as of September 30, 2024, after giving effect
to on a pro forma basis, the issuance of 411,776 shares of common stock under the Company’s at-the-market offering program at an
average price of $8.59 per share during February and March 2025, and after the issuance of 108,000 shares of common stock for cash at
an exercise price of $3.91 per share, was approximately $26.0 million or $1.15 per share.

After giving effect to the
issuance of 3,898,852 shares of our common stock for aggregate gross proceeds of $29.9 million (assuming the exercise of all of the Warrants
for cash), after deducting estimated offering expenses, our pro forma as adjusted net tangible book value as of September 30, 2024 would
have been approximately $55.9 million, or approximately $2.10 per share of our common stock. This represents an immediate increase in
net tangible book value of $0.95 per share of our common stock to our existing stockholders and an immediate dilution in net tangible
book value of approximately $5.57 per share of our common stock to the holders who exercise the Warrants. The following table